25 years of historical data (2001–2025) · Healthcare · Medical - Healthcare Plans
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Elevance Health Inc. trades at 15.5x earnings, 11% below its 5-year average of 17.4x, sitting at the 52nd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 30%. On a free-cash-flow basis, the stock trades at 26.6x P/FCF, 43% above the 5-year average of 18.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $84.4B | $77.8B | $85.9B | $111.9B | $124.5B | $114.4B | $81.7B | $78.6B | $66.8B | $60.3B | $38.5B |
| Enterprise Value | $108.1B | $101.5B | $110.3B | $132.1B | $143.0B | $134.4B | $97.8B | $94.9B | $82.1B | $76.6B | $50.2B |
| P/E Ratio → | 15.47 | 13.96 | 14.37 | 18.70 | 21.13 | 18.74 | 17.86 | 16.35 | 18.51 | 15.68 | 15.61 |
| P/S Ratio | 0.42 | 0.39 | 0.49 | 0.65 | 0.80 | 0.83 | 0.67 | 0.75 | 0.73 | 0.67 | 0.45 |
| P/B Ratio | 1.96 | 1.77 | 2.07 | 2.84 | 3.43 | 3.17 | 2.46 | 2.48 | 2.34 | 2.27 | 1.54 |
| P/FCF | 26.58 | 24.50 | 18.87 | 16.55 | 17.19 | 15.72 | 8.45 | 15.77 | 25.50 | 17.75 | 14.71 |
| P/OCF | 19.67 | 18.12 | 14.79 | 13.89 | 14.83 | 13.68 | 7.64 | 12.97 | 17.45 | 14.40 | 12.03 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Elevance Health Inc.'s enterprise value stands at 11.2x EBITDA, 8% below its 5-year average of 12.2x. The Healthcare sector median is 14.2x, placing the stock at a 21% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.51 | 0.62 | 0.77 | 0.91 | 0.97 | 0.80 | 0.91 | 0.89 | 0.85 | 0.59 |
| EV / EBITDA | 11.19 | 10.51 | 10.73 | 12.59 | 14.12 | 13.12 | 11.03 | 12.06 | 11.78 | 13.03 | 7.93 |
| EV / EBIT | 13.33 | 12.51 | 12.14 | 15.10 | 16.92 | 15.41 | 13.92 | 14.10 | 14.10 | 16.28 | 9.51 |
| EV / FCF | — | 31.98 | 24.24 | 19.52 | 19.73 | 18.47 | 10.11 | 19.04 | 31.33 | 22.56 | 19.15 |
Margins and return-on-capital ratios measuring operating efficiency
Elevance Health Inc. earns an operating margin of 4.1%. Operating margins have compressed from 5.1% to 4.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 13.3% is modest. ROIC of 9.1% represents adequate returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 25.6% | 25.6% | 27.9% | 27.4% | 25.5% | 26.0% | 27.8% | 21.5% | 21.9% | 19.8% | 21.4% |
| Operating Margin | 4.1% | 4.1% | 5.0% | 5.1% | 5.4% | 6.5% | 6.3% | 6.5% | 6.3% | 5.5% | 6.4% |
| Net Profit Margin | 2.8% | 2.8% | 3.4% | 3.5% | 3.8% | 4.4% | 3.8% | 4.6% | 4.1% | 4.3% | 2.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 13.3% | 13.3% | 14.8% | 15.8% | 16.3% | 17.6% | 14.1% | 16.0% | 13.6% | 14.9% | 10.3% |
| ROA | 4.8% | 4.8% | 5.3% | 5.7% | 5.9% | 6.6% | 5.5% | 6.4% | 5.2% | 5.6% | 3.8% |
| ROIC | 9.1% | 9.1% | 10.6% | 11.5% | 11.4% | 12.7% | 11.9% | 11.0% | 10.1% | 9.4% | 11.1% |
| ROCE | 8.2% | 8.2% | 9.5% | 10.1% | 10.2% | 11.3% | 10.8% | 10.4% | 9.4% | 8.4% | 9.7% |
Solvency and debt-coverage ratios — lower is generally safer
Elevance Health Inc. carries a Debt/EBITDA ratio of 3.4x, which is moderately leveraged (7% above the sector average of 3.2x). Net debt stands at $23.7B ($33.2B total debt minus $9.5B cash). Interest coverage of 5.8x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.75 | 0.75 | 0.79 | 0.68 | 0.71 | 0.69 | 0.66 | 0.67 | 0.67 | 0.75 | 0.63 |
| Debt / EBITDA | 3.44 | 3.44 | 3.18 | 2.54 | 2.55 | 2.43 | 2.46 | 2.70 | 2.76 | 3.39 | 2.48 |
| Net Debt / Equity | — | 0.54 | 0.59 | 0.51 | 0.51 | 0.55 | 0.48 | 0.51 | 0.54 | 0.62 | 0.46 |
| Net Debt / EBITDA | 2.46 | 2.46 | 2.37 | 1.92 | 1.82 | 1.95 | 1.82 | 2.07 | 2.19 | 2.78 | 1.84 |
| Debt / FCF | — | 7.48 | 5.36 | 2.98 | 2.54 | 2.75 | 1.67 | 3.26 | 5.83 | 4.81 | 4.45 |
| Interest Coverage | 5.79 | 5.79 | 7.67 | 8.49 | 9.93 | 10.93 | 8.96 | 9.02 | 7.73 | 6.36 | 7.30 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.24x means Elevance Health Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.97x to 1.24x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.24 | 1.24 | 1.10 | 0.97 | 1.03 | 0.94 | 1.14 | 1.11 | 1.13 | 0.93 | 1.07 |
| Quick Ratio | 1.24 | 1.24 | 1.10 | 0.97 | 1.03 | 0.94 | 1.14 | 1.11 | 1.13 | 0.93 | 1.07 |
| Cash Ratio | 0.48 | 0.48 | 0.43 | 0.33 | 0.40 | 0.31 | 0.47 | 0.44 | 0.42 | 0.34 | 0.44 |
| Asset Turnover | — | 1.64 | 1.51 | 1.57 | 1.52 | 1.42 | 1.38 | 1.33 | 1.27 | 1.26 | 1.28 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Elevance Health Inc. returns 4.9% to shareholders annually — split between a 1.8% dividend yield and 3.1% buyback yield. The payout ratio of 27.0% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 6.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.8% | 2.0% | 1.8% | 1.2% | 1.0% | 1.0% | 1.2% | 1.0% | 1.2% | 1.2% | 1.8% |
| Payout Ratio | 27.0% | 27.0% | 25.2% | 23.3% | 20.9% | 18.1% | 20.9% | 17.0% | 20.7% | 18.3% | 27.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.5% | 7.2% | 7.0% | 5.3% | 4.7% | 5.3% | 5.6% | 6.1% | 5.4% | 6.4% | 6.4% |
| FCF Yield | 3.8% | 4.1% | 5.3% | 6.0% | 5.8% | 6.4% | 11.8% | 6.3% | 3.9% | 5.6% | 6.8% |
| Buyback Yield | 3.1% | 3.4% | 3.4% | 2.4% | 1.9% | 1.7% | 3.3% | 2.2% | 2.5% | 3.3% | 0.2% |
| Total Shareholder Yield | 4.9% | 5.3% | 5.1% | 3.6% | 2.8% | 2.6% | 4.5% | 3.2% | 3.7% | 4.5% | 1.9% |
| Shares Outstanding | — | $222M | $233M | $237M | $243M | $247M | $254M | $260M | $254M | $268M | $268M |
Compare ELV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $84B | 15.5 | 11.2 | 26.6 | 25.6% | 4.1% | 13.3% | 9.1% | 3.4 | |
| $364B | 30.3 | 17.9 | 22.6 | 18.5% | 4.2% | 11.8% | 9.2% | 3.4 | |
| $125B | 70.7 | 14.0 | 16.1 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 | |
| $74B | 12.6 | 8.3 | 8.8 | 9.5% | 3.3% | 14.3% | 10.4% | 2.7 | |
| $43B | 36.7 | 22.9 | 115.5 | 14.5% | 1.1% | 7.0% | 4.1% | 5.7 | |
| $30B | -4.5 | — | 7.0 | 12.2% | -3.9% | -28.7% | -21.6% | — | |
| $10B | 21.9 | 10.1 | — | 9.0% | 1.7% | 11.0% | 17.4% | 4.0 | |
| $7B | -16.8 | — | 7.0 | 14.4% | -3.4% | -44.4% | — | — | |
| $3B | -29.4 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — | |
| $4B | -5908.1 | 93.4 | 39.5 | 12.4% | 0.4% | -0.5% | — | 7.5 | |
| $1B | -2.0 | — | — | — | — | -310.8% | -242.1% | — | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 25 years · Updated daily
Deep dive into ELV consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ELV stock.
Elevance Health Inc.'s current P/E ratio is 15.5x. The historical average is 14.6x. This places it at the 52th percentile of its historical range.
Elevance Health Inc.'s current EV/EBITDA is 11.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.5x.
Elevance Health Inc.'s return on equity (ROE) is 13.3%. The historical average is 13.4%.
Based on historical data, Elevance Health Inc. is trading at a P/E of 15.5x. This is at the 52th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Elevance Health Inc.'s current dividend yield is 1.77% with a payout ratio of 27.0%.
Elevance Health Inc. has 25.6% gross margin and 4.1% operating margin.
Elevance Health Inc.'s Debt/EBITDA ratio is 3.4x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.